New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:22 EDTTROVTrovagene to study transrenal BRAF mutations in primary and metastatic cancers
Trovagene announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. Researchers will use Trovagene's proprietary transrenal DNA, or TrDNA, detection technology to evaluate BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate; stable disease; progression-free survival; and overall survival. Results from patients who receive therapy that reflects their BRAF mutation status will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status.
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
09:52 EDTTROVTrovagene price target raised to $13 from $10 at Maxim
Maxim raised Buy rated Trovagene's price target to $13 following the presentation at the 2015 European Lung Cancer Conference demonstrating high clinical utility of its Precision Cancer platform.
April 17, 2015
12:21 EDTTROVOn The Fly: Top stock stories at midday
Subscribe for More Information
10:31 EDTTROVTrovagene says ctDNA assay outperformed tissue biopsy in clinical study
Trovagene announced that clinical data presented at the 2015 European Lung Cancer Conference demonstrate that its urine-based Precision Cancer Monitoring platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. The abstract, titled Detection of EGFR T790M Mutation in Urinary Circulating Tumor DNA from Metastatic Non-Small Cell Lung Cancer Patients, was presented today by Hatim Husain, M.D., University of California, San Diego Moores Cancer Center during the ESMO-IASLC Best Abstracts session in Geneva, Switzerland. In an interim analysis of 34 patients from an ongoing clinical study, Trovagene's PCM platform detected the T790M mutation in all patients who were positive for the mutation in tissue biopsy. The company's urine-based assay identified additional patients as T790M-positive, including those who had clinical suspicion of T790M-progressive disease, but were either negative by tissue biopsy or had not yet undergone tissue biopsy for confirmation. Trovagene's PCM platform detected EGFR T790M resistance mutations months earlier than radiologic detection of progression in patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use